Search results
Results From The WOW.Com Content Network
Updated January 4, 2024 at 12:47 PM. Drugmaker Eli Lilly announced on Thursday a new website that will allow patients to get a weight loss drug prescription through a telehealth provider — a ...
Orforglipron ( LY-3502970) is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. [1] [2] It is easier to produce than GLP-1 agonists on the market in 2023 and is expected to be cheaper. [3]
Indianapolis-based Eli Lilly (no. 142 on the Fortune 500) is the maker of Mounjaro, classified as Type 2 diabetes drug but which has led to weight loss among patients, and Zepbound, an obesity ...
April 18, 2024 at 7:00 AM. Despite Eli Lilly’s assurances about an ample supply of its new weight loss drug Zepbound, the company is now facing widespread shortages just months after its ...
Novo Nordisk ( NVO) stock was trading down Thursday despite strong first quarter results, beating Wall Street consensus, led by the blockbuster GLP-1s Ozempic for diabetes and Wegovy for weight ...
An Alzheimer's drug from Eli Lilly slowed decline of the disease by up to 48%, or about 7 and a half months. The drug comes with risks of serious side effects including brain bleeds.
James Gottstein. James Barry "Jim" Gottstein [1] is a mostly retired Alaska based lawyer who practiced business law and public land law, and is well known as an attorney advocate for people diagnosed with serious mental illness. Gottstein has sought to check the growth in the administration of psychotropics, particularly to children.
In 2012, pharmaceutical executive John C. Lechleiter from Eli Lilly & Company initially proposed the IBRI. In 2013, Indiana governor Mike Pence announced the formation of the IBRI. Pence later worked with life sciences leaders to secure $25 million in startup funds from the state. In 2015, the IBRI hired David Broecker as CEO.